Gerresheimer: Bormioli Pharma boosts revenues and earnings Revenues +11.6%, Adjusted EBITDA +13.1% Organic development compared to pro forma figures Q1 2024: revenues -6.5%, adjusted EBITDA -9.3% Q1 significantly influenced by revenue shift in syringe business Guidance 2025 confirmed: organic revenue growth of 3-5% and adjusted EBITDA margin of [ … ]

Gerresheimer delivers solid results in the financial year 2024 despite market headwinds Organic growth: revenue +2.9%, adjusted EBITDA +4.1% Destocking in vial business partially offset by strong growth in medical devices Growth strategy execution: capacity expansions and higher revenue share from solutions for biologics Bormioli Pharma to boos [ … ]